Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

Terzman May. 13 at 12:04 AM

$INBX parts worth way more than whole .. mkt will figure that out and we will get to area this deserves 3-4x

1 · Reply

Jerrydean3112 May. 12 at 8:16 PM

$INBX the data shared yesterday wasn’t robust enough compared to other competitors in the space. Hence the selling. From analyst “Inhibrx reported a cORR of 44% with '106 + pembro compared to 21.4% with pembro alone. There are no PFS data available yet (4Q26E). The safety was described as manageable, consistent with immune activation. Peto historically delivered a ~73% ORR, which we view as materially higher than the 44% reported by Inhibrx today. Peto also addresses a broader population (CPS >1 vs. CPS >20 only) and has mature OS data that Inhibrx has yet to report.”

1 · Reply

RNASequencing May. 12 at 7:56 PM

$INBX who could’ve seen it coming

0 · Reply

Mike22332233 May. 12 at 6:04 PM

$INBX I will NOT be surprised if $INBX closes between $115-$125 today !!!

1 · Reply

Terzman May. 12 at 5:30 PM

$INBX added ty screaming brilliant potential here imho

0 · Reply

justiceforb_85 May. 12 at 4:40 PM

$INBX added more. Sell off is overdone.

0 · Reply

Mike22332233 May. 12 at 4:27 PM

$INBX BOUGHT more down here … a large institution unloaded today many of the shares that were bought under $50 … when the unloading is over (I think it is just about done), this will fly back up !!! … There was nothing bad in the data !!!!

0 · Reply

Roaring_Capybara May. 12 at 4:16 PM

$INBX Im BUYING NOW!!!!

0 · Reply

MBWallingford May. 12 at 3:42 PM

$INBX maybe the data showed some concerns. Anyone get any research reports.

0 · Reply

Monkey7779192 May. 12 at 3:02 PM

$INBX Oh crap. Should have shorted this.

0 · Reply

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 1 day ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:26 AM EDT - 1 day ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 1 day ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 4 days ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 18 days ago

Inhibrx initiated with an Outperform at LifeSci Capital

2026-04-22T16:50:17.000Z - 20 days ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 20 days ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 20 days ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 20 days ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 20 days ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 20 days ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 21 days ago

Inhibrx Biosciences Transcript: Study update

2026-04-21T20:24:03.000Z - 21 days ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 21 days ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 20, 2026, 5:03 PM EDT - 22 days ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 5 weeks ago

Inhibrx initiated with a Buy at Stifel

2026-03-19T20:10:58.000Z - 7 weeks ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 7 weeks ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 2, 2026, 4:00 PM EST - 2 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 5 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 5 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

2025-11-14T19:05:15.000Z - 6 months ago

Inhibrx options imply 7.3% move in share price post-earnings

Nov 14, 2025, 6:00 AM EST - 6 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 6 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

2025-10-24T09:55:27.000Z - 7 months ago

Why Is Inhibrx Biosciences Stock (INBX) Surging Today?

Oct 23, 2025, 6:39 PM EDT - 7 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

2025-10-23T20:45:32.000Z - 7 months ago

Inhibrx trading resumes

Oct 23, 2025, 4:30 PM EDT - 7 months ago

Inhibrx Biosciences Transcript: Study Result

2025-10-23T20:20:12.000Z - 7 months ago

Inhibrx reports positive topline results from registrational trial of ozekibart

2025-10-23T20:06:07.000Z - 7 months ago

Inhibrx trading halted, news pending

Oct 23, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 7 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Inhibrx Reports Second Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 2 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 16, 2022, 9:00 AM EST - 3 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 7, 2022, 4:05 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Terzman May. 13 at 12:04 AM

$INBX parts worth way more than whole .. mkt will figure that out and we will get to area this deserves 3-4x

1 · Reply

Jerrydean3112 May. 12 at 8:16 PM

1 · Reply

RNASequencing May. 12 at 7:56 PM

$INBX who could’ve seen it coming

0 · Reply

Mike22332233 May. 12 at 6:04 PM

$INBX I will NOT be surprised if $INBX closes between $115-$125 today !!!

1 · Reply

Terzman May. 12 at 5:30 PM

$INBX added ty screaming brilliant potential here imho

0 · Reply

justiceforb_85 May. 12 at 4:40 PM

$INBX added more. Sell off is overdone.

0 · Reply

Mike22332233 May. 12 at 4:27 PM

0 · Reply

Roaring_Capybara May. 12 at 4:16 PM

$INBX Im BUYING NOW!!!!

0 · Reply

MBWallingford May. 12 at 3:42 PM

$INBX maybe the data showed some concerns. Anyone get any research reports.

0 · Reply

Monkey7779192 May. 12 at 3:02 PM

$INBX Oh crap. Should have shorted this.

0 · Reply

MBWallingford May. 12 at 11:52 AM

$INBX the buyout offer is not imminent. Guessing price. They are going to want to complete Phase 3 testing to get the highest offer. He indicated that investors are willing to support the company. PIPE could be coming by year end. Testing gets expensive. It will be years and not months before company is taken out. Who knows. I like to think thru scenarios. Still a tremendous amount of risk. 20% short. This is not a lottery ticket. More risk here than people realize. CEO seems to quite good, which is rare.

0 · Reply

Roaring_Capybara May. 12 at 12:49 AM

$INBX Full enrollment for phase 3 = 2029 ???? That seems to be the buzz-kill here.

1 · Reply

Number99 May. 11 at 11:11 PM

$INBX Confusing. My armchair take is that the recent share price run-up following the Reuters article was largely driven by investor assumptions that the reported big pharma interest reflected positive interim data from 106. In that context, today’s data release may have simply validated expectations that were already priced into the stock, rather than providing a meaningful new upside surprise. I guess we need to wait for the progression-free survival / overall survival assessment later this year.

0 · Reply

Monkey7779192 May. 11 at 10:18 PM

$INBX Readouts now been like pumps and dumps. Risk and reward not worth buying before data. A bad data would have lost me 50 percent and good data lost me 20 percent on sell the news event. Its not worth it.

1 · Reply

MBWallingford May. 11 at 10:09 PM

$INBX I guess the good news is was priced in. Closed at the low. Certainly not what I expected.

0 · Reply

justiceforb_85 May. 11 at 9:07 PM

$INBX good data for INBRX-106 in 1L metastatic HNSCC with CPS >20. Company should be valued much higher.

0 · Reply

Roaring_Capybara May. 11 at 7:58 PM

$INBX Buy the rumor .........

0 · Reply

Mike22332233 May. 11 at 7:31 PM

$INBX The interim Phase 2 data for INBRX-106 was outstanding, as expected, with the INBRX-106 + KEYTRUDA combination achieving a cORR of 44.0% versus 21.4% with KEYTRUDA alone ... The $34 Bil a year KEYTRUDA franchise that MRK has is about to end soon as patents run out ... this is a way MRK can salvage that franchise, and re-start that patent clock!! .... MRK will buy out INBRX-106 from INBX .... I just don't know if it will be for $3.5 Bil ($240/shr) or $7 Bil ($480) ... and I don't know if it will be in 2 months or in 6 months !!!! ... and you still will own the rest of INBX, which is worth just as much !!!!! … Make sure to FOLLOW me for all the other special situations I cover …

1 · Reply

Chucklee9027y May. 11 at 6:19 PM

$INBX Imagine if they hadn’t come in with those numbers, would’ve easily crushed this—down 30%.

0 · Reply

Chucklee9027y May. 11 at 4:56 PM

$INBX not sure what to think

0 · Reply

MarketBeat May. 11 at 4:09 PM

https://marketbeat.com/a/8648524/ $INBX Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

0 · Reply

Chucklee9027y May. 11 at 1:30 PM

$INBX lets break 165!

0 · Reply

Market Cap	1.86B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	2.71

Volume	1,273,100
Avg Vol	405,326
Day's Range	N/A - N/A
Shares Out	14.61M
Stochastic %K	18%
Beta	3.88
Analysts	Sell
Price Target	$250.00